Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All metformin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 79% Improvement Relative Risk Case -44% Metformin for COVID-19  Blanc et al.  Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 179 patients in France Lower mortality (p=0.058) and more cases (p=0.12), not sig. c19early.org Blanc et al., GeroScience, July 2021 Favors metformin Favors control

Therapeutic prevention of COVID-19 in elderly: a case–control study

Blanc et al., GeroScience, doi:10.1007/s11357-021-00397-z
Jul 2021  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020
 
*, now known with p < 0.00000000001 from 89 studies.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 70+ treatments. c19early.org
Retrospective 179 patients in France exposed to COVID-19 showing, without statistical significance, a higher risk of cases, and a lower risk of mortality among cases with existing metformin treatment.
risk of death, 78.6% lower, RR 0.21, p = 0.06, treatment 1 of 14 (7.1%), control 25 of 75 (33.3%), NNT 3.8, COVID+.
risk of case, 43.7% higher, RR 1.44, p = 0.12, treatment 11 of 16 (68.8%), control 78 of 163 (47.9%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Blanc et al., 17 Jul 2021, retrospective, France, peer-reviewed, 22 authors.
This PaperMetforminAll
Therapeutic prevention of COVID-19 in elderly: a case–control study
Frederic Blanc, Cedric Waechter, Thomas Vogel, Benoit Schorr, Catherine Demuynck, Catherine Martin Hunyadi, Maxence Meyer, Denata Mutelica, Nadjiba Bougaa, Samira Fafi-Kremer, Lidia Calabrese, Elise Schmitt, Delphine Imperiale, Catherine Jehl, Alexandre Boussuge, Carmen Suna, François Weill, Alexia Matzinger, Candice Muller, Patrick Karcher, Georges Kaltenbach, Erik Sauleau
GeroScience, doi:10.1007/s11357-021-00397-z
15 days prior to RT-PCR (including antihypertensive drugs, antipsychotics, antibiotics, nonsteroidal anti-inflammatory drugs, proton pump inhibitors (PPIs), oral antidiabetics (OADs), corticosteroids, immunosuppressants), comorbidities, symptoms, laboratory values, and clinical outcome were all collected. COVID-pos patients more frequently had a history of diabetes (P = .016) and alcoholism (P = .023), a lower leukocyte count (P = .014) and a higher mortality rate -29.2% versus 14.4% -(P = .014) when compared to COVID-neg patients. Patients on PPIs were 2.3 times less likely (odds ratio [OR] = 0.4381, 95% confidence interval [CI] [0.2331, 0.8175], P = .0053) to develop COVID-19 infection, compared to those not on PPIs. No other treatment decreased or increased this risk. COVID-pos patients on antipsychotics (P = .0013) and OADs (P = .0153), particularly metformin (P = .0237), were less likely to die. Thus, patients on treatment with PPI were less likely to develop COVID-19 infection, and those on antipsychotics or metformin had a lower risk of mortality. However, prospective studies, including clinical trials, are needed to confirm or not these findings.
Author contribution Data and materials availability After publication, the data will be made available to others on reasonable requests to the corresponding author. A proposal with detailed description of study objectives and statistical analysis plan will be needed for evaluation of the reasonability of requests. Additional materials might also be required during the process of evaluation. Deidentified participant data will be provided after approval from the corresponding author. Declarations Ethics approval and consent to participate Ethics committee "Faculté de Médecine de Strasbourg" number CE-2020-68. Consent for publication Yes. Conflict of interest The authors declare no competing interests. Supplementary Information The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s11357-021-00397-z. Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Almario, Chey, Spiegel, Increased risk of COVID-19 among users of proton pump inhibitors, Am J Gastroenterol, doi:10.14309/ajg.0000000000000798
Baden, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine, N Engl J Med, doi:10.1056/NEJMoa2035389
Caruso, Chest CT features of COVID-19 in Rome, Radiology, doi:10.1148/radiol.2020201237
Cetin, Increased risk of death associated with the use of proton pump inhibitors in dementia patients and controls -a pharmacoepidemiological claims data analysis, Eur J Neurol, doi:10.1111/ene.14252
Chang, Letter: suppression of herpetic recurrence by chlorpromazine, N Engl J Med
Chen, Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study, J Gerontol Ser A, doi:10.1093/gerona/glaa089
Crouse, Grimes, Li, Might, Ovalle et al., Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes, Front Endocrinol, doi:10.3389/fendo.2020.600439
Geerlings, Hoepelman, Immune dysfunction in patients with diabetes mellitus (DM), FEMS Immunol Med Microbiol
Gomm, Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis, JAMA Neurol, doi:10.1001/jamaneurol.2015.4791
Gordon, A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drugrepurposing
Grasselli, Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region Italy, JAMA, doi:10.1001/jama.2020.5394
Gurwitz, Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics, Drug Dev Res, doi:10.1002/ddr.21656
Hacisuleyman, Vaccine breakthrough infections with SARS-CoV-2 variants, N Engl J Med, doi:10.1056/NEJMoa2105000
Homolak, Kodvanj, Widely available lysosome targeting agents should be considered as a potential therapy for COVID-19
Hreinsson, Palsdóttir, Bjornsson, The association of drugs with severity and specific causes of acute lower gastrointestinal bleeding, J Clin Gastroenterol
Hálfdánarson, Proton-pump inhibitors among adults: a nationwide drug-utilization study, Ther Adv Gastroenterol, doi:10.1177/1756284818777943
Jones-Brando, Buthod, Holland, Yolken, Torrey, Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1, Schizophr Res, doi:10.1016/s0920-9964(97)00007-8
Klompas, Coronavirus disease 2019 (COVID-19): protecting hospitals from the invisible, Ann Intern Med, doi:10.7326/m20-0751
Lee, Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma, Oncotarget, doi:10.18632/oncotarget.5319
Lee, Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching, Gut, doi:10.1136/gutjnl-2020-322248
Luxenburger, Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor?, J Intern Med, doi:10.1111/joim.1312110.1111/joim.13121
Mehta, Yeligar, Elon, Brown, Guidot, Alcoholism causes alveolar macrophage zinc deficiency and immune dysfunction, Am J Respir Crit Care Med
Moatti, The French response to COVID-19: intrinsic difficulties at the interface of science, public health, and policy
Nikolich-Zugich, Knox, Rios, Natt, Bhattacharya et al., regarding pathogenesis, immune responses, and outcomes, doi:10.1007/s11357-020-00186-0
Polack, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N Engl J Med, doi:10.1056/NEJMoa2034577
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, JAMA, doi:10.1001/jama.2020.6775
Simmons, Reeves, Rennekamp, Amberg, Piefer et al., Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry, Proc Natl Acad Sci U S A, doi:10.1073/pnas.0306446101
Spugnini, Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors, J Transl Med, doi:10.1186/1479-5876-9-221
Team, Vital surveillances: the epidemiological characteristics of an outbreak of 2019 Novel coronavirus diseases (COVID-19)-China, 2020 China, CDC Wkly
Vaduganathan, Vardeny, Michel, Mcmurray, Pfeffer et al., Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19, N Engl J Med, doi:10.1056/NEJMsr2005760
Voysey, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, doi:10.1016/S0140-6736(20)32661-1.
Who E, COVID-19 weekly surveillance report
Wunderlich, Fey, Sydow, Antiviral effect of haloperidol on Rauscher murine leukemia virus, Archiv fur Geschwulstforschung
Yang, Shen, Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19, Int J Biol Sci, doi:10.7150/ijbs.45498
Zhu, A novel coronavirus from patients with pneumonia in China, N Engl J Med, doi:10.1056/NEJMoa2001017
{ 'DOI': '10.1007/s11357-021-00397-z', 'ISSN': ['2509-2715', '2509-2723'], 'URL': 'http://dx.doi.org/10.1007/s11357-021-00397-z', 'alternative-id': ['397'], 'assertion': [ { 'group': {'label': 'Article History', 'name': 'ArticleHistory'}, 'label': 'Received', 'name': 'received', 'order': 1, 'value': '1 May 2020'}, { 'group': {'label': 'Article History', 'name': 'ArticleHistory'}, 'label': 'Accepted', 'name': 'accepted', 'order': 2, 'value': '31 May 2021'}, { 'group': {'label': 'Article History', 'name': 'ArticleHistory'}, 'label': 'First Online', 'name': 'first_online', 'order': 3, 'value': '17 July 2021'}, {'group': {'label': 'Declarations', 'name': 'EthicsHeading'}, 'name': 'Ethics', 'order': 1}, { 'group': {'label': 'Ethics approval and consent to participate', 'name': 'EthicsHeading'}, 'name': 'Ethics', 'order': 2, 'value': 'Ethics committee “Faculté de Médecine de Strasbourg” number CE-2020–68.'}, { 'group': {'label': 'Consent for publication', 'name': 'EthicsHeading'}, 'name': 'Ethics', 'order': 3, 'value': 'Yes.'}, { 'group': {'label': 'Conflict of interest', 'name': 'EthicsHeading'}, 'name': 'Ethics', 'order': 4, 'value': 'The authors declare no competing interests.'}, { 'label': 'Free to read', 'name': 'free', 'value': 'This content has been made available to all.'}], 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-6714-3247', 'affiliation': [], 'authenticated-orcid': False, 'family': 'Blanc', 'given': 'Frederic', 'sequence': 'first'}, {'affiliation': [], 'family': 'Waechter', 'given': 'Cedric', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Vogel', 'given': 'Thomas', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Schorr', 'given': 'Benoit', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Demuynck', 'given': 'Catherine', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Hunyadi', 'given': 'Catherine Martin', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Meyer', 'given': 'Maxence', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Mutelica', 'given': 'Denata', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Bougaa', 'given': 'Nadjiba', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Fafi-Kremer', 'given': 'Samira', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Calabrese', 'given': 'Lidia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Schmitt', 'given': 'Elise', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Imperiale', 'given': 'Delphine', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Jehl', 'given': 'Catherine', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Boussuge', 'given': 'Alexandre', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Suna', 'given': 'Carmen', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Weill', 'given': 'François', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Matzinger', 'given': 'Alexia', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Muller', 'given': 'Candice', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Karcher', 'given': 'Patrick', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Kaltenbach', 'given': 'Georges', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Sauleau', 'given': 'Erik', 'sequence': 'additional'}], 'container-title': ['GeroScience'], 'content-domain': {'crossmark-restriction': False, 'domain': ['link.springer.com']}, 'created': {'date-parts': [[2021, 7, 17]], 'date-time': '2021-07-17T04:02:41Z', 'timestamp': 1626494561000}, 'deposited': { 'date-parts': [[2021, 11, 17]], 'date-time': '2021-11-17T10:14:07Z', 'timestamp': 1637144047000}, 'indexed': {'date-parts': [[2022, 2, 5]], 'date-time': '2022-02-05T16:05:59Z', 'timestamp': 1644077159370}, 'is-referenced-by-count': 1, 'issn-type': [{'type': 'print', 'value': '2509-2715'}, {'type': 'electronic', 'value': '2509-2723'}], 'issue': '5', 'issued': {'date-parts': [[2021, 7, 17]]}, 'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2021, 10]]}}, 'language': 'en', 'license': [ { 'URL': 'https://www.springer.com/tdm', 'content-version': 'tdm', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 7, 17]], 'date-time': '2021-07-17T00:00:00Z', 'timestamp': 1626480000000}}, { 'URL': 'https://www.springer.com/tdm', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2021, 7, 17]], 'date-time': '2021-07-17T00:00:00Z', 'timestamp': 1626480000000}}], 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11357-021-00397-z.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s11357-021-00397-z/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11357-021-00397-z.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '297', 'original-title': [], 'page': '2333-2343', 'prefix': '10.1007', 'published': {'date-parts': [[2021, 7, 17]]}, 'published-online': {'date-parts': [[2021, 7, 17]]}, 'published-print': {'date-parts': [[2021, 10]]}, 'publisher': 'Springer Science and Business Media LLC', 'reference': [ { 'DOI': '10.14309/ajg.0000000000000798', 'author': 'CV Almario', 'doi-asserted-by': 'publisher', 'first-page': '1707', 'journal-title': 'Am J Gastroenterol', 'key': '397_CR1', 'unstructured': 'Almario CV, Chey WD, Spiegel BMR. Increased risk of COVID-19 among users ' 'of proton pump inhibitors. Am J Gastroenterol. 2020;115:1707–15. ' 'https://doi.org/10.14309/ajg.0000000000000798.', 'volume': '115', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2035389', 'author': 'LR Baden', 'doi-asserted-by': 'publisher', 'first-page': '403', 'journal-title': 'N Engl J Med', 'key': '397_CR2', 'unstructured': 'Baden LR, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 ' 'vaccine. N Engl J Med. 2020;384:403–16. ' 'https://doi.org/10.1056/NEJMoa2035389.', 'volume': '384', 'year': '2020'}, { 'DOI': '10.1148/radiol.2020201237', 'doi-asserted-by': 'publisher', 'key': '397_CR3', 'unstructured': 'Caruso D et al. Chest CT features of COVID-19 in Rome, Italy. Radiology. ' '2020; 201237. https://doi.org/10.1148/radiol.2020201237'}, { 'DOI': '10.1111/ene.14252', 'doi-asserted-by': 'publisher', 'key': '397_CR4', 'unstructured': 'Cetin H et al. Increased risk of death associated with the use of proton ' 'pump inhibitors in dementia patients and controls – a ' 'pharmacoepidemiological claims data analysis. Eur J Neurol. 2020. ' 'https://doi.org/10.1111/ene.14252'}, { 'author': 'TW Chang', 'first-page': '153', 'journal-title': 'N Engl J Med', 'key': '397_CR5', 'unstructured': 'Chang TW. Letter: suppression of herpetic recurrence by chlorpromazine. ' 'N Engl J Med. 1975;293:153–4.', 'volume': '293', 'year': '1975'}, { 'DOI': '10.1093/gerona/glaa089', 'author': 'T Chen', 'doi-asserted-by': 'publisher', 'journal-title': 'J Gerontol Ser A', 'key': '397_CR6', 'unstructured': 'Chen T, et al. Clinical characteristics and outcomes of older patients ' 'with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a ' 'single-centered, retrospective study. J Gerontol Ser A. 2020. ' 'https://doi.org/10.1093/gerona/glaa089.', 'year': '2020'}, { 'DOI': '10.3389/fendo.2020.600439', 'doi-asserted-by': 'publisher', 'key': '397_CR7', 'unstructured': 'Crouse AB, Grimes T, Li P, Might M, Ovalle F, Shalev A. Metformin use is ' 'associated with reduced mortality in a diverse population with COVID-19 ' 'and diabetes. Front Endocrinol. 2021; 11. ' 'https://doi.org/10.3389/fendo.2020.600439'}, { 'DOI': '10.1111/j.1574-695X.1999.tb01397.x', 'author': 'SE Geerlings', 'doi-asserted-by': 'publisher', 'first-page': '259', 'journal-title': 'FEMS Immunol Med Microbiol', 'key': '397_CR8', 'unstructured': 'Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes ' 'mellitus (DM). FEMS Immunol Med Microbiol. 1999;26:259–65.', 'volume': '26', 'year': '1999'}, { 'DOI': '10.1001/jamaneurol.2015.4791', 'author': 'W Gomm', 'doi-asserted-by': 'publisher', 'first-page': '410', 'journal-title': 'JAMA Neurol', 'key': '397_CR9', 'unstructured': 'Gomm W, et al. Association of proton pump inhibitors with risk of ' 'dementia: a pharmacoepidemiological claims data analysis. JAMA Neurol. ' '2016;73:410–6. https://doi.org/10.1001/jamaneurol.2015.4791.', 'volume': '73', 'year': '2016'}, { 'key': '397_CR10', 'unstructured': 'Gordon DE, et al. A SARS-CoV-2-human protein-protein interaction map ' 'reveals drug targets and potential drug-repurposing. BioRxiv. 2020.'}, { 'DOI': '10.1001/jama.2020.5394', 'author': 'G Grasselli', 'doi-asserted-by': 'publisher', 'journal-title': 'JAMA', 'key': '397_CR11', 'unstructured': 'Grasselli G, et al. Baseline characteristics and outcomes of 1591 ' 'patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy ' 'Region Italy. JAMA. 2020. https://doi.org/10.1001/jama.2020.5394.', 'year': '2020'}, { 'DOI': '10.1002/ddr.21656', 'author': 'D Gurwitz', 'doi-asserted-by': 'publisher', 'journal-title': 'Drug Dev Res.', 'key': '397_CR12', 'unstructured': 'Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 ' 'therapeutics. Drug Dev Res. 2020. https://doi.org/10.1002/ddr.21656.', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2105000', 'author': 'E Hacisuleyman', 'doi-asserted-by': 'publisher', 'journal-title': 'N Engl J Med', 'key': '397_CR13', 'unstructured': 'Hacisuleyman E, et al. Vaccine breakthrough infections with SARS-CoV-2 ' 'variants. N Engl J Med. 2021. https://doi.org/10.1056/NEJMoa2105000.', 'year': '2021'}, { 'DOI': '10.1177/1756284818777943', 'author': 'ÓÖ Hálfdánarson', 'doi-asserted-by': 'publisher', 'first-page': '175628481877794', 'journal-title': 'Ther Adv Gastroenterol', 'key': '397_CR14', 'unstructured': 'Hálfdánarson ÓÖ, et al. Proton-pump inhibitors among adults: a ' 'nationwide drug-utilization study. Ther Adv Gastroenterol. ' '2018;11:1756284818777943. https://doi.org/10.1177/1756284818777943.', 'volume': '11', 'year': '2018'}, { 'DOI': '10.20944/preprints202003.0345.v2', 'doi-asserted-by': 'crossref', 'key': '397_CR15', 'unstructured': 'Homolak J, Kodvanj I. Widely available lysosome targeting agents should ' 'be considered as a potential therapy for COVID-19. 2020.'}, { 'DOI': '10.1097/MCG.0000000000000393', 'author': 'JP Hreinsson', 'doi-asserted-by': 'publisher', 'first-page': '408', 'journal-title': 'J Clin Gastroenterol', 'key': '397_CR16', 'unstructured': 'Hreinsson JP, Palsdóttir S, Bjornsson ES. The association of drugs with ' 'severity and specific causes of acute lower gastrointestinal bleeding. J ' 'Clin Gastroenterol. 2016;50:408–13.', 'volume': '50', 'year': '2016'}, { 'DOI': '10.1016/s0920-9964(97)00007-8', 'author': 'LV Jones-Brando', 'doi-asserted-by': 'publisher', 'first-page': '63', 'journal-title': 'Schizophr Res', 'key': '397_CR17', 'unstructured': 'Jones-Brando LV, Buthod JL, Holland LE, Yolken RH, Torrey EF. ' 'Metabolites of the antipsychotic agent clozapine inhibit the replication ' 'of human immunodeficiency virus type 1. Schizophr Res. 1997;25:63–70. ' 'https://doi.org/10.1016/s0920-9964(97)00007-8.', 'volume': '25', 'year': '1997'}, { 'DOI': '10.7326/m20-0751', 'author': 'M Klompas', 'doi-asserted-by': 'publisher', 'journal-title': 'Ann Intern Med', 'key': '397_CR18', 'unstructured': 'Klompas M. Coronavirus disease 2019 (COVID-19): protecting hospitals ' 'from the invisible. Ann Intern Med. 2020. ' 'https://doi.org/10.7326/m20-0751.', 'year': '2020'}, { 'DOI': '10.1136/gutjnl-2020-322248', 'author': 'SW Lee', 'doi-asserted-by': 'publisher', 'journal-title': 'Gut', 'key': '397_CR19', 'unstructured': 'Lee SW, et al. Severe clinical outcomes of COVID-19 associated with ' 'proton pump inhibitors: a nationwide cohort study with propensity score ' 'matching. Gut. 2020. https://doi.org/10.1136/gutjnl-2020-322248.', 'year': '2020'}, { 'DOI': '10.18632/oncotarget.5319', 'author': 'YY Lee', 'doi-asserted-by': 'publisher', 'first-page': '35040', 'journal-title': 'Oncotarget', 'key': '397_CR20', 'unstructured': 'Lee YY, et al. Proton pump inhibitors enhance the effects of cytotoxic ' 'agents in chemoresistant epithelial ovarian carcinoma. Oncotarget. ' '2015;6:35040–50. https://doi.org/10.18632/oncotarget.5319.', 'volume': '6', 'year': '2015'}, { 'DOI': '10.1111/joim.1312110.1111/joim.13121', 'author': 'H Luxenburger', 'doi-asserted-by': 'publisher', 'journal-title': 'J Intern Med', 'key': '397_CR21', 'unstructured': 'Luxenburger H, et al. Treatment with proton pump inhibitors increases ' 'the risk of secondary infections and ARDS in hospitalized patients with ' 'COVID-19: coincidence or underestimated risk factor? J Intern Med. 2020. ' 'https://doi.org/10.1111/joim.1312110.1111/joim.13121.', 'year': '2020'}, { 'DOI': '10.1164/rccm.201301-0061OC', 'author': 'AJ Mehta', 'doi-asserted-by': 'publisher', 'first-page': '716', 'journal-title': 'Am J Respir Crit Care Med', 'key': '397_CR22', 'unstructured': 'Mehta AJ, Yeligar SM, Elon L, Brown LA, Guidot DM. Alcoholism causes ' 'alveolar macrophage zinc deficiency and immune dysfunction. Am J Respir ' 'Crit Care Med. 2013;188:716–23.', 'volume': '188', 'year': '2013'}, { 'DOI': '10.1016/S2468-2667(20)30087-6', 'doi-asserted-by': 'crossref', 'key': '397_CR23', 'unstructured': 'Moatti J-P. The French response to COVID-19: intrinsic difficulties at ' 'the interface of science, public health, and policy. Lancet Public ' 'Health. 2020.'}, { 'DOI': '10.1007/s11357-020-00186-0', 'author': 'J Nikolich-Zugich', 'doi-asserted-by': 'publisher', 'journal-title': 'GeroScience', 'key': '397_CR24', 'unstructured': 'Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. ' 'SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding ' 'pathogenesis, immune responses, and outcomes. GeroScience. 2020. ' 'https://doi.org/10.1007/s11357-020-00186-0.', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2034577', 'author': 'FP Polack', 'doi-asserted-by': 'publisher', 'journal-title': 'N Engl J Med', 'key': '397_CR25', 'unstructured': 'Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 ' 'vaccine. N Engl J Med. 2020. https://doi.org/10.1056/NEJMoa2034577.', 'year': '2020'}, { 'DOI': '10.1001/jama.2020.6775', 'author': 'S Richardson', 'doi-asserted-by': 'publisher', 'journal-title': 'JAMA', 'key': '397_CR26', 'unstructured': 'Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson ' 'KW, Consortium atNC-R. Presenting characteristics, comorbidities, and ' 'outcomes among 5700 patients hospitalized with COVID-19 in the New York ' 'City Area. JAMA. 2020. https://doi.org/10.1001/jama.2020.6775.', 'year': '2020'}, { 'DOI': '10.1073/pnas.0306446101', 'author': 'G Simmons', 'doi-asserted-by': 'publisher', 'first-page': '4240', 'journal-title': 'Proc Natl Acad Sci U S A', 'key': '397_CR27', 'unstructured': 'Simmons G, Reeves JD, Rennekamp AJ, Amberg SM, Piefer AJ, Bates P. ' 'Characterization of severe acute respiratory syndrome-associated ' 'coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry. Proc ' 'Natl Acad Sci U S A. 2004;101:4240–5. ' 'https://doi.org/10.1073/pnas.0306446101.', 'volume': '101', 'year': '2004'}, { 'DOI': '10.1186/1479-5876-9-221', 'author': 'EP Spugnini', 'doi-asserted-by': 'publisher', 'first-page': '221', 'journal-title': 'J Transl Med', 'key': '397_CR28', 'unstructured': 'Spugnini EP, et al. Lansoprazole as a rescue agent in chemoresistant ' 'tumors: a phase I/II study in companion animals with spontaneously ' 'occurring tumors. J Transl Med. 2011;9:221. ' 'https://doi.org/10.1186/1479-5876-9-221.', 'volume': '9', 'year': '2011'}, { 'author': 'Team TNCPERE', 'first-page': '113', 'journal-title': 'CDC Wkly', 'key': '397_CR29', 'unstructured': 'Team TNCPERE. Vital surveillances: the epidemiological characteristics ' 'of an outbreak of 2019 Novel coronavirus diseases (COVID-19)—China, 2020 ' 'China. CDC Wkly. 2020;2:113–22.', 'volume': '2', 'year': '2020'}, { 'DOI': '10.1056/NEJMsr2005760', 'doi-asserted-by': 'publisher', 'key': '397_CR30', 'unstructured': 'Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon ' 'SD. Renin-angiotensin-aldosterone system inhibitors in patients with ' 'Covid-19. 2020. N Engl J Med. https://doi.org/10.1056/NEJMsr2005760.'}, { 'DOI': '10.1016/S0140-6736(20)32661-1.', 'doi-asserted-by': 'publisher', 'key': '397_CR31', 'unstructured': 'Voysey M, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine ' '(AZD1222) against SARS-CoV-2: an interim analysis of four randomised ' 'controlled trials in Brazil, South Africa, and the UK. Lancet. ' 'https://doi.org/10.1016/S0140-6736(20)32661-1.'}, { 'key': '397_CR32', 'unstructured': 'WHO (2020a) ' 'https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2. ' 'Accessed 6 July 2021.'}, { 'key': '397_CR33', 'unstructured': 'WHO E (2020b) COVID-19 weekly surveillance report, data of the week of ' '23–29 nov 2021 ' 'https://www.eurowhoint/en/health-topics/health-emergencies/coronavirus-covid-19/previous-weekly-surveillance-reports/previous-weekly-surveillance-reports-2020/data-for-the-week-of-23-29-november-2020-epi-week-48. ' 'Accessed April, 2021'}, { 'author': 'V Wunderlich', 'first-page': '758', 'journal-title': 'Archiv fur Geschwulstforschung', 'key': '397_CR34', 'unstructured': 'Wunderlich V, Fey F, Sydow G. Antiviral effect of haloperidol on ' 'Rauscher murine leukemia virus. Archiv fur Geschwulstforschung. ' '1980;50:758–62.', 'volume': '50', 'year': '1980'}, { 'DOI': '10.7150/ijbs.45498', 'author': 'N Yang', 'doi-asserted-by': 'publisher', 'first-page': '1724', 'journal-title': 'Int J Biol Sci', 'key': '397_CR35', 'unstructured': 'Yang N, Shen H-M. Targeting the endocytic pathway and autophagy process ' 'as a novel therapeutic strategy in COVID-19. Int J Biol Sci. ' '2020;16:1724–31. https://doi.org/10.7150/ijbs.45498.', 'volume': '16', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2001017', 'author': 'N Zhu', 'doi-asserted-by': 'publisher', 'first-page': '727', 'journal-title': 'N Engl J Med', 'key': '397_CR36', 'unstructured': 'Zhu N, et al. (2020) A novel coronavirus from patients with pneumonia in ' 'China. N Engl J Med. 2019;382:727–33. ' 'https://doi.org/10.1056/NEJMoa2001017.', 'volume': '382', 'year': '2019'}], 'reference-count': 36, 'references-count': 36, 'relation': {}, 'score': 1, 'short-container-title': ['GeroScience'], 'short-title': [], 'source': 'Crossref', 'subject': ['Geriatrics and Gerontology', 'Aging'], 'subtitle': [], 'title': ['Therapeutic prevention of COVID-19 in elderly: a case–control study'], 'type': 'journal-article', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'volume': '43'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit